Literature DB >> 12649174

Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens.

Vera Balz1, Kathrin Scheckenbach, Karl Götte, Ulrike Bockmühl, Iver Petersen, Henning Bier.   

Abstract

Mutations and interaction with high-risk human papillomavirus (HPV) E6 oncoprotein are well-established mechanisms of p53 inactivation. In a series of 123 unselected squamous cell carcinomas of the head and neck (SCCHN), we performed sequence analysis of the entire coding region of p53 transcript and determined the presence of the E6 transcripts of HPV 16 and 18. Aberrant p53 transcripts were identified in 97 (79%) SCCHN. HPV 16 and/or 18 E6 transcripts were detected in 37 (30%) tumor specimens, including 20 (77%) of the 26 p53 wild-type tumors. The likely inactivation of p53 in 117 (95%) of the 123 SCCHN suggests that this event could be obligatory in the multistep process of carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649174

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

Review 1.  Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.

Authors:  K Scheckenbach; M Wagenmann; M Freund; J Schipper; H Hanenberg
Journal:  Klin Padiatr       Date:  2012-04-13       Impact factor: 1.349

2.  HUMAN PAPILLOMAVIRUS ASSOCIATION WITH HEAD AND NECK CANCERS: UNDERSTANDING VIRUS BIOLOGY AND USING IT IN THE DEVELOPMENT OF CANCER DIAGNOSTICS.

Authors:  Katerina Strati; Paul F Lambert
Journal:  Expert Opin Med Diagn       Date:  2008-01-01

Review 3.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

Review 4.  The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

Authors:  Daniel E Johnson
Journal:  Endocr Relat Cancer       Date:  2014-03-21       Impact factor: 5.678

Review 5.  Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.

Authors:  Albert B DeLeo; Theresa L Whiteside
Journal:  Expert Rev Vaccines       Date:  2008-09       Impact factor: 5.217

Review 6.  Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination.

Authors:  Maura L Gillison
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

7.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 8.  Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas.

Authors:  Görkem Eskiizmir
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-09-01

Review 9.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

10.  Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.

Authors:  Changyou Li; Daniel E Johnson
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.